Interpace Biosciences (OTCQX: IDXG) Investment Thesis

22% Growth. 62% Margins. 10x Earnings.

To read our full disclaimer, click here.

The headline said “revenue down 29%.”

Most investors wouldn’t look any further.

But buried in the press release was a different story entirely.

Pro forma revenue - the business that actually remains - grew 22%. Test volumes hit all-time highs. Gross margins expanded to 62%. Net income came in at $0.9 million for the …